Progen abandons PI-88

By Dylan Bushell-Embling and Kate McDonald
Wednesday, 23 July, 2008

Brisbane's Progen Pharmaceuticals [ASX: PGL] has abandoned its PI-88 liver cancer trials, sending its share price tumbling by almost 50 per cent.

PI-88, a heparin sulphate mimic with anti-angiogenic and anti-metastatic properties, was undergoing Phase III trials prior to the termination, but was experiencing significant delays in patient recruitment and obtaining regulatory approval, the company said.

Another factor contributing to the decision was the recent news that pharma giant Bayer and collaborator Onyx Pharmaceuticals have commenced trials of a competitor product, Nexavar, a kinase inhibitor targeting angiogenesis.

Progen also had trouble finding a partner willing to help develop and commercialise the product.

Progen will shortly commence discussions with its partners and others over the sale of the compound, it said.

The company, which began as a pharmaceutical manufacturing concern, said it would now concentrate on mergers and acquisitions.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd